%PDF-1.4
%
93 0 obj
<>
endobj
90 0 obj
<>
endobj
154 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T13:33:35Z
2024-03-28T11:56:22-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T11:56:22-07:00
application/pdf
Heather
2001-554.march
uuid:9588eaaf-1dd1-11b2-0a00-310a277d8900
uuid:9588eab2-1dd1-11b2-0a00-d30000000000
endstream
endobj
79 0 obj
<>
endobj
80 0 obj
<>
endobj
94 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
22 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
45 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
53 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
66 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
69 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
184 0 obj
[188 0 R]
endobj
185 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 72 714.5293 Tm
(inhibition of leukotriene B4. Carrageenan-induced gonarthritis)Tj
0 -1.25 TD
[(studied in dogs. )54.9 (Acta Orthop Scand 1990;61:207-12.)]TJ
-1.875 -1.25 Td
[(30.)-625 (Atik OS. Leukotriene B4 and prostaglandin E2-like activity in)]TJ
1.875 -1.25 Td
(synovial fluid in osteoarthritis. Prostaglandins Leukot Essent Fatty)Tj
T*
(Acids 1990;39:253-4.)Tj
-1.875 -1.25 Td
[(31.)-375 (Carty )17.7 (TJ, Sweeney FJ, Grif)17.8 (fiths RJ, et al. )17.7 (T)69.8 (enidap inhibits )]TJ
1.625 -1.25 Td
(5-lipoxygenase product formation in vitro, but this activity is not)Tj
T*
(observed in three animal models. Inflamm Res 1997;46:168-79.)Tj
-1.625 -1.25 Td
[(32.)-375 (Bonnet C, Bertin P)110.8 (, Cook-Moreau J, Chable-Rabinovitch H, )17.8 (T)34.9 (reves)]TJ
1.625 -1.25 Td
(R, Rigaud M. Lipoxygenase products and expression of )Tj
T*
(5-lipoxygenase and 5-lipoxygenase-activating protein in human)Tj
T*
(cultured synovial cells. Prostaglandins 1995;50:127-35.)Tj
-1.625 -1.25 Td
[(33.)-375 (Ford-Hutchinson )54.9 (A)80.1 (W)91.8 (. Leukotriene B4 in inflammation. Crit Rev)]TJ
1.625 -1.25 Td
(Immunol 1990;10:1-12.)Tj
-1.625 -1.25 Td
[(34.)-375 (Dennis EA. )17.7 (The growing phospholipase )54.8 (A)]TJ
0 Tw 5.2 0 0 5.2 206.3829 571.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 211.1829 574.5293 Tm
(superfamily of signal)Tj
0 Tc -17.6479 -1.25 Td
[(transduction enzymes. )17.8 (T)34.9 (rends Biochem Sci 1997;22:1-2.)]TJ
-1.625 -1.25 Td
[(35.)-375 (Lin LL, Lin )54.8 (A)92 (Y)129.2 (, DeW)39.8 (itt DL. Interleukin-1)]TJ
/T1_0 1 Tf
0 Tw 18.6478 0 Td
(\002)Tj
/TT0 1 Tf
0.02499 Tw 0.9059 0 Td
(induces the)Tj
-17.9287 -1.25 Td
[(accumulation of cytosolic phospholipase )54.9 (A)]TJ
0 Tw 5.2 0 0 5.2 208.5422 541.8893 Tm
(2)Tj
0.02499 Tw 8 0 0 8 213.3422 544.5293 Tm
(and the release of)Tj
-17.9178 -1.25 Td
(prostaglandin E)Tj
0 Tw 5.2 0 0 5.2 120.6297 531.8893 Tm
(2)Tj
0.02499 Tw 8 0 0 8 125.4297 534.5293 Tm
(in human fibroblasts. J Biol Chem 1992;)Tj
0 Tw -6.9287 -1.25 Td
(267:23451-4.)Tj
0.02499 Tw -1.625 -1.25 Td
[(36.)-375 (Zhang FX, Kirschning CJ, Mancinelli R, et al. Bacterial)]TJ
1.625 -1.25 Td
[(lipopolysaccharide activates nuclear factor)19.8 (-kappa B through )]TJ
T*
(interleukin-1 signaling mediators in cultured human dermal )Tj
T*
(endothelial cells and mononuclear phagocytes. J Biol Chem)Tj
0 Tw T*
[(1999;274:761)36.9 (1-4.)]TJ
0.02499 Tw -1.625 -1.25 Td
[(37.)-375 (Muzio M, Natoli G, Saccani S, Levrero M, Mantovani )54.9 (A. )17.8 (The human)]TJ
1.625 -1.25 Td
[(toll signaling pathway: diver)17.8 (gence of nuclear factor kappa B and)]TJ
-0.00011 Tc T*
(JNK/SAPK activation upstream of tumor necrosis factor )Tj
T*
[(receptor)19.7 (-associated factor 6 \(TRAF6\). J Exp Med 1998;)]TJ
0 Tc 0 Tw T*
(187:2097-101.)Tj
-0.00011 Tc 0.02499 Tw -1.625 -1.25 Td
[(38.)-375.1 (Gashler )54.8 (A, Sukhatme )17.7 (VP)110.7 (. Early growth response protein 1 \(Egr)19.7 (-1\):)]TJ
1.625 -1.25 Td
(prototype of a zinc-finger family of transcription factors. Prog)Tj
0 Tc T*
[(Nucleic )54.9 (Acid Res Mol Biol 1995;50:191-224.)]TJ
-0.00011 Tc -1.625 -1.25 Td
[(39.)-375.1 (Silverman ES, Du J, )17.7 (W)39.7 (illiams )54.8 (AJ, )17.7 (W)79.7 (adgaonkar R, Drazen JM,)]TJ
1.625 -1.25 Td
[(Collins )17.7 (T)73.9 (. cAMP-response-element-binding-protein-binding protein)]TJ
T*
(\(CBP\) and p300 are transcriptional co-activators of early growth)Tj
0 Tc T*
[(response factor)19.8 (-1 \(Egr)19.8 (-1\). Biochem J 1998;336:183-9.)]TJ
-0.00011 Tc -1.625 -1.25 Td
[(40.)-375.1 (Di Battista JA, Martel-Pelletier J, Pelletier J. Suppression of tumor)]TJ
1.625 -1.25 Td
(necrosis factor gene expression by prostaglandin E\(2\). Role of early)Tj
T*
(growth response protein-1. Osteoarthritis Cartilage 1999;7:395-8.)Tj
-1.625 -1.25 Td
[(41.)-375.1 (Di Battista JA, Jovanovic DV)128.8 (, He )36.8 (Y)129 (, Morin N, Martel-Pelletier J,)]TJ
0 Tc 1.625 -1.25 Td
[(Pelletier JP)110.8 (. Regulation of basal and lymphokine-induced IL-1\337 and)]TJ
-0.0002 Tc 0 Tw T*
(TNF-)Tj
/T1_0 1 Tf
0 Tc [-0.2 (\002)]TJ
/TT0 1 Tf
0.02499 Tw 3.1273 0 Td
(gene expression by prostaglandin E)Tj
0 Tw 5.2 0 0 5.2 209.5587 291.8893 Tm
(2)Tj
0.02499 Tw 8 0 0 8 214.3586 294.5293 Tm
(in human)Tj
-18.0448 -1.25 Td
(monocyte/macrophages. Elucidation of post-receptor signaling)Tj
T*
[(pathways [abstract]. )54.8 (Arthritis Rheum 1999;42 Suppl:S199.)]TJ
-1.625 -1.25 Td
[(42.)-375 (Seitz M, Loetscher P)110.8 (, Dewald B, )17.7 (T)69.8 (owbin H, Baggiolini M. In vitro)]TJ
1.625 -1.25 Td
[(modulation of cytokine, cytokine inhibitor)39.8 (, and prostaglandin E)]TJ
T*
(release from blood mononuclear cells and synovial fibroblasts by)Tj
T*
(antirheumatic drugs. J Rheumatol 1997;24:1471-6.)Tj
31.375 60 Td
[(43.)-375 (Caughey GE, Pouliot M, Cleland LG, James MJ. Regulation of)]TJ
-0.00011 Tc 1.625 -1.25 Td
[(tumor necrosis factor)19.7 (-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw [0.3 (\002)]TJ
/TT0 1 Tf
0.0249 Tw 9.7645 0 Td
[(and IL-1\337 synthesis by thromboxane )54.8 (A2 in)]TJ
-9.7645 -1.25 Td
(nonadherent human monocytes. J Immunol 1997;158:351-8.)Tj
-1.625 -1.25 Td
[(44.)-375 (T)69.8 (akahashi S, Inoue )17.8 (T)74 (, Higaki M, Mizushima )36.9 (Y)129.1 (. Cyclooxygenase)]TJ
1.625 -1.25 Td
[(inhibitors enhance the production of tissue inhibitor)19.8 (-1 of)]TJ
-0.00011 Tc T*
(metalloproteinases \(TIMP-1\) and pro-matrix metalloproteinase-1)Tj
T*
(\(proMMP-1\) in human rheumatoid synovial fibroblasts. Inflamm Res)Tj
0 Tc 0 Tw T*
(1997;46:320-3.)Tj
-0.00011 Tc 0.02499 Tw -1.625 -1.25 Td
[(45.)-375.1 (Zhang )36.8 (Y)129.1 (, McCluskey K, Fujii K, )17.7 (W)79.7 (ahl LM. Dif)17.7 (ferential regulation of)]TJ
0 Tc 1.625 -1.25 Td
[(monocyte matrix metalloproteinase and )17.7 (TIMP-1 production by )]TJ
-0.0002 Tc 0 Tw T*
(TNF-)Tj
/T1_0 1 Tf
0 Tc [-0.2 (\002)]TJ
/TT0 1 Tf
0.02499 Tw [0.1 (, granulocyte-macrophage CSF)79.8 (, and IL-1\337 through)]TJ
T*
(prostaglandin-dependent and \226independent mechanisms. J Immunol)Tj
0 Tw T*
(1998;161:3071-6.)Tj
-0.00011 Tc 0.02499 Tw -1.625 -1.25 Td
[(46.)-375.1 (Di Battista JA, Martel-Pelletier J, Kazushi I, Nagai )36.8 (Y)129 (,)-0.1 ( Zafarullah M,)]TJ
1.625 -1.25 Td
[(Pelletier JP)110.7 (. Prostaglandins E)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 427.9125 571.8893 Tm
(2)Tj
0.02499 Tw 8 0 0 8 432.7125 574.5293 Tm
(and E)Tj
0 Tw 5.2 0 0 5.2 451.35 571.8893 Tm
(1)Tj
0.02499 Tw 8 0 0 8 456.15 574.5293 Tm
(inhibit the cytokine-stimulated)Tj
-15.2687 -1.25 Td
(expression of metalloproteinases in normal human synovial )Tj
T*
[(fibroblasts: Mediation by cyclic )54.8 (AMP)-238.1 (signalling pathway)64.9 (. Lab Invest)]TJ
0 Tw T*
(1994;71:270-8.)Tj
-0.00011 Tc 0.02499 Tw -1.625 -1.25 Td
[(47.)-375.1 (Fernandes JC, Martel-Pelletier J, Pelletier JP)110.7 (. Gene therapy for)]TJ
1.625 -1.25 Td
[(osteoarthritis: new perspectives for the twenty-first century)64.8 (. Clin)]TJ
0 Tc T*
(Orthop 2000;379 Suppl:S262-72.)Tj
-0.00011 Tc -1.625 -1.25 Td
[(48.)-375.1 (Raychaudhuri B, Fisher CJ, Farver CF)79.7 (, et al. Interleukin 10-mediated)]TJ
0 Tc 1.625 -1.25 Td
(inhibition of inflammatory cytokine production by human alveolar)Tj
T*
(macrophages. Cytokine 2000;12:1348-55.)Tj
-0.00011 Tc -1.625 -1.25 Td
[(49.)-375.1 (Deleuran B, Iversen L, Deleuran M, et al. Interleukin 13 suppresses)]TJ
0 Tc 1.625 -1.25 Td
(cytokine production and stimulates the production of 15-HETE in)Tj
T*
[(PBMC. )54.9 (A)-219.8 (comparison between IL-4 and IL-13. Cytokine)]TJ
0 Tw T*
(1995;7:319-24.)Tj
-0.00011 Tc 0.02499 Tw -1.625 -1.25 Td
[(50.)-375.1 (Deleuran B, Iversen L, Kristensen M, et al. Interleukin-8 secretion)]TJ
0 Tc 1.625 -1.25 Td
(and 15-lipoxygenase activity in rheumatoid arthritis: in vitro )Tj
T*
[(anti-inflammatory ef)17.8 (fects by interleukin-4 and interleukin-10, but not)]TJ
T*
(by interleukin-1 receptor antagonist protein. Br J Rheumatol)Tj
0 Tw T*
(1994;33:520-5.)Tj
-0.00011 Tc 0.02499 Tw -1.625 -1.25 Td
[(51.)-375.1 (Alaaeddine N, Di Battista JA, Pelletier JP)110.7 (, Kiansa K, Cloutier JM,)]TJ
1.625 -1.25 Td
(Martel-Pelletier J. Inhibition of tumor necrosis factor alpha-induced)Tj
0 Tc T*
(prostaglandin E2 production by the antiinflammatory cytokines)Tj
T*
(interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic)Tj
T*
[(synovial fibroblasts: distinct tar)17.8 (geting in the signaling pathways.)]TJ
T*
(Arthritis Rheum 1999;42:710-8.)Tj
-0.00011 Tc -1.625 -1.25 Td
[(52.)-375.1 (Hart PH, Hunt EK, Bonder CS, )17.7 (W)79.7 (atson CJ, Finlay-Jones JJ.)]TJ
0 Tc 1.625 -1.25 Td
[(Regulation of surface and soluble )17.7 (TNF receptor expression on)]TJ
T*
(human monocytes and synovial fluid macrophages by IL-4 and )Tj
T*
(IL-10. J Immunol 1996;157:3672-80.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(He, et al: Eicosanoid dependent MMP)-257.2 (synthesis)]TJ
0 Tw 61.4375 -0.0313 Td
(553)Tj
ET
0 0 0 0 scn
/GS0 gs
103.35 58.08 407.5 -10.83 re
f*
0.5 w
103.35 58.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_1 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
101 0 obj
<>
endobj
137 0 obj
<>
endobj
159 0 obj
<>
endobj
107 0 obj
<>
endobj
98 0 obj
<>
endobj
97 0 obj
<>
endobj
127 0 obj
<>stream
HV lޛ]1v93xmR.s .>0sȁX +C$M BJh08&*((Bp(@
HUv! A
ÿW̼J@嶞z bcq|}h*Wr"#8 Ŝ²ewt_P^(~X0+>):ȯw)SGwo jkx(^,̕m(CAkOy`F[Zy7LRDm>Q Q+D{uܬ[VHˆ;TkKI[qa?`o]Wk
#ިXmg5a2Gq?uy9*q -p]"RtD#x;M!jlx0#jz";sbY^kWO#-Fc.su
/&hjY?VBC
:g 3dLjƭgG#(_b@Wq+˔jٺdVyfN}П'a*y:b"At"Wl)Y&g˃UQWֵ0N8Y^D>#8
Y7$5={>>eg. Ph)"DW/7₌qҐCE%CVO7:峊93*q sbwX±a+߸W8N<Є۸xDQ"#V$s
76]-cDX,jXM=q̗>9Y.<-W
(.NTwhTZv:z?z%4%T:f9h+ݪYzvfhxH:8
x&cQYVs빁ns#$~WOxG u.z0|f4^
$L9MQWp0b%kⶸj2Jdge!GBVe]\/?[_)ȣ2VTWReE٪lWP#呚UG{~MhZ6K{]jkuna:
X[u:li?"cҋK
,9|wOPNA>?r85b'xIm8RH :װ.xZBCxRkU:1LV?7bJ6o ѽ[̌>K)%9)cB|\lϵi&uCS)574c0
?MgmL6ӟвfKK w5tXc|\5t)^ia
7^yW(Ҕy`KbX3뷹Jr)Lu
9RkK3u3bgYĠ]=
Լzpp/%E]ӎwfC.==؞7^,?u%>/3S/ g04),3r?Ϯc;`J-GjKOfFΞ?l
z3$2F7X*~YelEȘ5c|ͼiI(2{-555OOb͈'1qL?ԥau DvD$(ZJRleB(P&~*$[}^|&u$uZv>|1eu˶'IHBHZOzEZR5cqH_R~9 簍IrvVʺE}=Z'U-vˌg0q725ln))H'zjs9w&uUVgR )O源\m*,;w7cf\ԏ$_Htu!Q%ź.Ȟy:-ys~S3_sjۯtT)9o u Ucf耙ec:=$/cv='$vc81VaKW~
5,mI
I,ڂԑ/KC/(k$k:` )mX&f0i,}{wwAI
-azZr%B=Y4 %P'7AۅuD-"4 -M
Nϕ+M݀EY{`}:sL܇Ia;^pC̀"&[wxI<s< T
A]08,DjvK>0 13sO yA.C^}N2Ga G9byDWL
h+` h
71;JލGQcƘD,'#ё!2"#tO鰟#2GNbgU4G'Cfj U'ur Ȣ7: I?PN):y(C'U4tc Y'$2H A': aB:١ec K52چq[fn۔۔4;RUnjWTr[[CP.nE֪L*`Rת,hUJZus97aaӰ2VJUX)
+:L++JagZ